Braunstein Scott 4
4 · RAPT Therapeutics, Inc. · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
RAPT Director Scott Braunstein Receives 4,956 RSU Award
What Happened
Scott Braunstein, a director of RAPT Therapeutics (RAPT), received a grant of 4,956 restricted stock units (RSUs) on January 30, 2026. The Form 4 reports the acquisition at $0.00 per share (total reported cost $0). The RSUs are awards (code A) and do not represent immediately tradable shares until they vest.
Key Details
- Transaction date: 2026-01-30 (reported on Form 4 filed 2026-02-02).
- Transaction type/code: Grant/Award (A).
- Shares/units granted: 4,956 RSUs; $0.00 per unit (total $0 reported).
- Vesting: Per footnote F1, these RSUs fully vest on the first anniversary of the grant date and each RSU converts into one share upon vesting.
- Shares owned after transaction: Not specified in the provided filing details.
- Timeliness: Filing dated 2026-02-02 for a 2026-01-30 grant (filed within the standard Form 4 reporting window).
Context
This is a routine non-employee director compensation grant under the company’s director compensation policy. RSU awards are typical for directors and are contingent on future vesting, so they do not indicate an immediate purchase or sale of stock. The economic value to the insider depends on RAPT’s share price at vesting.
Insider Transaction Report
- Award
Common Stock
[F1]2026-01-30+4,956→ 4,956 total
Footnotes (1)
- [F1]Represents the annual grant of restricted stock units ("RSUs") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as currently in effect, which fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.